Wooin Lee

Contact Information

337 Bio Pharm Complex
789 South Limestone Street
Lexington, KY 40536-0596

Phone: 859-257-6065
Fax: 859-257-7564

Contact by email


  • Assistant Professor
    Department of Pharmaceutical Sciences


  • B.S., Pharmacy
    Seoul National University, 1993
  • M.S., Pharmaceutics
    National University, Korea, 1995
  • Ph.D., Pharmaceutics
    University at Buffalo, SUNY, New York, 2001
  • Post-Doctoral Scholar & Fellow
    Vanderbilt University Medical Center, 2002-2004

Wooin Lee, Ph.D.

Dr. Lee's major research interest is to understand the genetic and molecular bases for interindividual variability associated with chemotherapy. One project in the laboratory is to investigate the role of drug efflux and influx transporters and the impact of their genetic variations in cancer therapy. Other projects examine the immunoproteasome as a novel anticancer target and the impact of genetic variations associated with the immunoproteasome subunits on the effectiveness of the immunoproteasome-targeting approach. As ongoing collaborative efforts with clinical oncologists, we investigate the impact of host and tumoral factors influencing clinical response and toxicity of chemotherapy and assess the variability in the pharmacokinetics of anticancer agents as a potential cause for differing clinical outcome.

Selected Publications

  • Thakkar N, Kim K, Jang ER, Han S, Kim K, Kim D, Merchant N, Lockhart AC, Lee W. A cancer-specific variant of the SLCO1B3 gene encodes a novel human organic anion transporting polypeptide 1B3 (OATP1B3) localized mainly in the cytoplasm of colon and pancreatic cancer cells. Mol Pharm. 2013 Jan 7;10(1):406-16. (PMID:23215050)
  • Miller Z, Ao L, Kim KB, Lee W. Inhibitors of the immunoproteasome: current status and future directions.Curr Pharm Des. 2013;19(22):4140-51. (PMID: 23181576)
  • Park JE, Ao L, Miller Z, Kim K, Wu Y, Jang ER, Lee EY, Kim KB, Lee W. PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit β1i expressed in multiple types of solid cancer. PLoS One. 2013 Sep 9;8(9):e73732. (PMID: 24040045)
  • Han S*, Kim K*, Thakkar N*, Kim D, Lee W. Role of hypoxia inducible factor-1α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer. Biochem Pharmacol. 2013 Sep 15;86(6):816-23. (*, equally contributed)(PMID:23924606)
  • Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris HA 3rd, Zamboni WC. Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors. Eur J Clin Pharmacol. 2013 Aug 30. [Epub ahead of print] (PMID: 23989300)
  • Jang ER, Lee NR, Han S, Wu Y, Sharma LK, Carmony KC, Marks J, Lee DM, Ban JO, Wehenkel M, Hong JT, Kim KB, Lee W. Revisiting the role of the immunoproteasome in the activation of the canonical NF-κB pathway. Mol Biosyst. 2012 Sep;8(9):2295-302. (PMID:22722901)
  • Sharma LK, Lee NR, Jang ER, Lei B, Zhan CG, Lee W, Kim KB. Activity-based near-infrared fluorescent probe for LMP7: a chemical proteomics tool for the immunoproteasome in living cells. Chembiochem. 2012 Sep 3;13(13):1899-903. (PMID:22807337)
  • Ao L, Wu Y, Kim D, Jang ER, Kim K, Lee DM, Kim KB, Lee W. Development of peptide-based reversing agents for P-glycoprotein-mediated resistance to carfilzomib. Mol Pharm 2012;9(8):2197−2205. (PMID: 22734651)
  • Infante JR, Keedy VL, Jones SF, Zamboni WC, Chan E, Bendell JC, Lee W, Wu H, Ikeda S, Kodaira H, Rothenberg ML, Burris HA III. Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012 Nov;70(5):699-705. (PMID: 22941375)
  • Lafleur B, Lee W, Billhiemer D, Lockhart C, Liu J, Merchant N. Statistical methods for assays with limits of detection: Serum bile acid as a differentiator between patients with normal colons, adenomas, and colorectal cancer. J Carcinog. 2011;10:12. (PMID:21712958)
  • Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Liao CY, Hartley JA, Berlin JD, Rothenberg ML. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. Clin Cancer Res. 2011 Jun 1;17(11):3794-802. (PMID:21346148)
  • Lee W, Kim KB. The immunoproteasome: an emerging therapeutic target. Curr Top Med Chem. 2011 Dec;11(23):2923-30. (PMID:21824107)
  • Janjigian YY, Lee W, Kris MG, Miller VA, Krug LM, Azzoli CG, Senturk E, Calcutt MW, Rizvi NA. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol. 2010 Apr;65(5):833-8. (PMID:19672598)
  • Jang ER, Lee W, Kim KB. Targeted Degradation of Proteins by PROTACs (PROteolysis TArgeting Chimeric molecules). Curr Protoc Chem Biol. 2010 Jun 1;2(2):71-87. (PMID:23836551)
  • Lee W, Patel JH, Lockhart AC. Novel targets in esophageal and gastric cancer: beyond antiangiogenesis. Expert Opin Investig Drugs. 2009 Sep;18(9):1351-64. (PMID:19642951)
  • Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB, El-Rifai W. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res. 2008 Dec 15;68(24):10315-23. (PMID:19074900)
  • Lockhart AC, Harris E, Lafleur BJ, Merchant NB, Washington MK, Resnick MB, Yeatman TJ, Lee W. Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome. Clin Exp Gastroenterol. 2008;1:1-7. (PMID:21677819)
  • Wade Calcutt M, Lee W, Puzanov I, Rothenberg ML, Hachey DL. Determination of chemically reduced pyrrolobenzodiazepine SJG-136 in human plasma by HPLC-MS/MS: application to an anticancer phase I dose escalation study. J Mass Spectrom. 2008 Jan;43(1):42-52. (PMID:17683023)

Website Links

Lee Lab Website (http://openwetware.org/wiki/Lee)

Scholar Profile
page last modified: October 02 2013     

© University of Kentucky College of Pharmacy
Official Site of the University of Kentucky College of Pharmacy